JP2017529366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529366A5 JP2017529366A5 JP2017515843A JP2017515843A JP2017529366A5 JP 2017529366 A5 JP2017529366 A5 JP 2017529366A5 JP 2017515843 A JP2017515843 A JP 2017515843A JP 2017515843 A JP2017515843 A JP 2017515843A JP 2017529366 A5 JP2017529366 A5 JP 2017529366A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic composition
- cancer
- group
- adi
- progression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 239000004475 Arginine Substances 0.000 claims description 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 108010082340 Arginine deiminase Proteins 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims 33
- 230000001225 therapeutic effect Effects 0.000 claims 28
- 108010075480 ADI PEG20 Proteins 0.000 claims 8
- 230000005764 inhibitory process Effects 0.000 claims 7
- 208000024891 symptom Diseases 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 235000001014 amino acid Nutrition 0.000 claims 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- QXZGLTYKKZKGLN-UHFFFAOYSA-N 4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)ON1C(=O)CCC1=O QXZGLTYKKZKGLN-UHFFFAOYSA-N 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 230000009260 cross reactivity Effects 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003700 epoxy group Chemical group 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000005462 imide group Chemical group 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000006320 pegylation Effects 0.000 claims 1
- 230000002797 proteolythic effect Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 235000013477 citrulline Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020175282A JP6961061B2 (ja) | 2014-09-16 | 2020-10-19 | 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対する交差反応性が低減したアルギニンデイミナーゼ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051182P | 2014-09-16 | 2014-09-16 | |
| US62/051,182 | 2014-09-16 | ||
| PCT/US2015/050354 WO2016044376A1 (en) | 2014-09-16 | 2015-09-16 | Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020175282A Division JP6961061B2 (ja) | 2014-09-16 | 2020-10-19 | 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対する交差反応性が低減したアルギニンデイミナーゼ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529366A JP2017529366A (ja) | 2017-10-05 |
| JP2017529366A5 true JP2017529366A5 (enExample) | 2019-10-24 |
| JP6782230B2 JP6782230B2 (ja) | 2020-11-11 |
Family
ID=55453727
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515843A Active JP6782230B2 (ja) | 2014-09-16 | 2015-09-16 | 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対する交差反応性が低減したアルギニンデイミナーゼ |
| JP2020175282A Active JP6961061B2 (ja) | 2014-09-16 | 2020-10-19 | 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対する交差反応性が低減したアルギニンデイミナーゼ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020175282A Active JP6961061B2 (ja) | 2014-09-16 | 2020-10-19 | 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対する交差反応性が低減したアルギニンデイミナーゼ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9789170B2 (enExample) |
| EP (2) | EP3193913B1 (enExample) |
| JP (2) | JP6782230B2 (enExample) |
| KR (1) | KR102730989B1 (enExample) |
| CN (2) | CN107073085B (enExample) |
| AU (1) | AU2015317848B2 (enExample) |
| CA (1) | CA2961602A1 (enExample) |
| ES (1) | ES2915382T3 (enExample) |
| SG (2) | SG10202002557SA (enExample) |
| TW (2) | TWI708612B (enExample) |
| WO (1) | WO2016044376A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2805360T3 (es) | 2013-03-15 | 2021-02-11 | Tdw Group | Arginina desiminasa con reactividad cruzada reducida hacia anticuerpos para ADI - PEG 20 para el tratamiento del cáncer |
| US10463721B2 (en) | 2014-03-18 | 2019-11-05 | Tdw Group | Engineered chimeric pegylated ADI and methods of use |
| SG10202002557SA (en) | 2014-09-16 | 2020-04-29 | Tdw Group | Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment |
| CN109414426B (zh) | 2016-07-05 | 2024-12-20 | 北极星药业集团股份有限公司 | 使用精氨酸耗竭剂的组合癌症免疫疗法 |
| WO2018035497A1 (en) | 2016-08-18 | 2018-02-22 | Meharry Medical College | Inhibitors of intracellular invasion |
| WO2018063801A1 (en) * | 2016-09-29 | 2018-04-05 | Meharry Medical College | Bacterial inhibitors |
| CA3039796A1 (en) * | 2016-11-02 | 2018-05-11 | Polaris Group | Formulations of pegylated arginine deiminase |
| WO2018183671A1 (en) | 2017-03-29 | 2018-10-04 | Tdw Group | Protein conjugates |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5804183A (en) | 1997-01-31 | 1998-09-08 | Enzon, Inc. | Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same |
| US6635462B1 (en) | 1997-05-12 | 2003-10-21 | Phoenix Pharmacologies, Inc. | Mutated form of arginine deiminase |
| US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
| US6180387B1 (en) | 1997-08-11 | 2001-01-30 | Smithkline Beecham Corporation | Arginine deiminase |
| IT1298918B1 (it) | 1998-02-20 | 2000-02-07 | Mendes Srl | Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche |
| WO2002009741A1 (en) | 2000-07-27 | 2002-02-07 | Angiolab, Inc. | The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis |
| AU2001289132A1 (en) | 2000-11-28 | 2002-06-11 | Phoenix Pharmacologics, Inc. | Modified arginine deiminase |
| CA2506244C (en) | 2002-11-18 | 2012-10-30 | Phoenix Pharmacologics, Inc. | Methods for inhibiting viral replication in vivo |
| CN1536079A (zh) * | 2003-04-09 | 2004-10-13 | 上海复旦张江生物医药股份有限公司 | 修饰的精氨酸脱亚氨酶 |
| CA2524173A1 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for diagnosing aml and mds differential gene expression |
| WO2005052145A2 (en) | 2003-10-07 | 2005-06-09 | University Of Florida | Recombinant alkaliizing bacteria |
| CN101002945B (zh) | 2006-01-20 | 2012-09-05 | 清华大学 | 一种用于肿瘤治疗的新型复合物 |
| EP2173732A4 (en) | 2007-07-04 | 2011-09-07 | Reddys Lab Ltd Dr | PROCESSES FOR THE PREPARATION OF DOCETAXEL AND POLYMORPHIC |
| US20090238813A1 (en) | 2007-12-28 | 2009-09-24 | Board Of Regents, The University Of Texas System | Compositions And Methods For Engineered Human Arginine Deiminases |
| WO2010083312A2 (en) | 2009-01-14 | 2010-07-22 | The Trustees Of The University Of Pennsylvania | Micro-rna biomarker in cancer |
| CN101591649B (zh) * | 2009-07-10 | 2013-02-13 | 江苏泰康生物医药有限公司 | 甲氧基聚乙二醇修饰的精氨酸脱亚氨酶及其制备与应用 |
| US20110111403A1 (en) | 2009-10-30 | 2011-05-12 | Life Technologies Corporation | Multi-primer assay for mycoplasma detection |
| CN101812438B (zh) * | 2010-03-25 | 2014-08-27 | 江苏泰康生物医药有限公司 | 一种精氨酸脱亚氨酶突变体及其制备与应用 |
| WO2011151704A2 (en) | 2010-06-02 | 2011-12-08 | Fresenius Kabi Oncology Ltd. | Stable pharmaceutical compositions of rapamycin esters |
| US20120148559A1 (en) | 2010-12-01 | 2012-06-14 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
| US8663967B2 (en) | 2011-08-22 | 2014-03-04 | Jiangsu T-Mab Biopharma Co., Ltd. | Arginine deiminase mutant and preparation and application thereof |
| CN103797025B (zh) | 2012-04-04 | 2018-03-23 | 波拉里集团 | 用精氨酸脱亚氨酶治疗的方法 |
| ES2805360T3 (es) * | 2013-03-15 | 2021-02-11 | Tdw Group | Arginina desiminasa con reactividad cruzada reducida hacia anticuerpos para ADI - PEG 20 para el tratamiento del cáncer |
| US10463721B2 (en) * | 2014-03-18 | 2019-11-05 | Tdw Group | Engineered chimeric pegylated ADI and methods of use |
| SG10202002557SA (en) | 2014-09-16 | 2020-04-29 | Tdw Group | Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment |
-
2015
- 2015-09-16 SG SG10202002557SA patent/SG10202002557SA/en unknown
- 2015-09-16 CA CA2961602A patent/CA2961602A1/en active Pending
- 2015-09-16 EP EP15842576.9A patent/EP3193913B1/en active Active
- 2015-09-16 SG SG11201702103XA patent/SG11201702103XA/en unknown
- 2015-09-16 TW TW104130733A patent/TWI708612B/zh active
- 2015-09-16 EP EP22172372.9A patent/EP4104853A1/en active Pending
- 2015-09-16 TW TW109133681A patent/TWI775160B/zh active
- 2015-09-16 CN CN201580057712.XA patent/CN107073085B/zh active Active
- 2015-09-16 US US14/855,661 patent/US9789170B2/en active Active
- 2015-09-16 KR KR1020177010232A patent/KR102730989B1/ko active Active
- 2015-09-16 ES ES15842576T patent/ES2915382T3/es active Active
- 2015-09-16 CN CN202210112607.3A patent/CN114522225B/zh active Active
- 2015-09-16 WO PCT/US2015/050354 patent/WO2016044376A1/en not_active Ceased
- 2015-09-16 AU AU2015317848A patent/AU2015317848B2/en active Active
- 2015-09-16 JP JP2017515843A patent/JP6782230B2/ja active Active
-
2020
- 2020-10-19 JP JP2020175282A patent/JP6961061B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017529366A5 (enExample) | ||
| JP2016519069A5 (enExample) | ||
| RU2015141932A (ru) | Аргининдеиминаза с пониженной перекрестной реактивностью к антителам adi-peg 20 для лечения рака | |
| Ciaffaglione et al. | Mutual prodrugs of 5‐fluorouracil: From a classic chemotherapeutic agent to novel potential anticancer drugs | |
| Brandi et al. | Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies | |
| Pan et al. | Mesoporous silica nanoparticles (MSNs)-based organic/inorganic hybrid nanocarriers loading 5-Fluorouracil for the treatment of colon cancer with improved anticancer efficacy | |
| Schepis et al. | State-of-the-art and upcoming innovations in pancreatic cancer care: a step forward to precision medicine | |
| Goodarzi et al. | CD 44‐targeted docetaxel conjugate for cancer cells and cancer stem‐like cells: a novel hyaluronic acid‐based drug delivery system | |
| Pan et al. | Synthesis of Long‐Circulating, Backbone Degradable HPMA Copolymer–Doxorubicin Conjugates and Evaluation of Molecular‐Weight‐Dependent Antitumor Efficacy | |
| Ljubimova et al. | Toxicity and efficacy evaluation of multiple targeted polymalic acid conjugates for triple-negative breast cancer treatment | |
| RU2011146654A (ru) | Способы лечения рака яичников с применением конъюгированного средства | |
| JP2017513516A5 (enExample) | ||
| KR20170084034A (ko) | 암 치료용 의약 조성물 제조에서의 아젤니디핀의 용도 | |
| JP2018104470A (ja) | アルギニンデイミナーゼを用いる処置方法 | |
| Yan et al. | Inhalable nanoparticles with enhanced cuproptosis and cGAS–STING activation for synergistic lung metastasis immunotherapy | |
| Ganbold et al. | Receptor-mediated delivery of therapeutic RNA by peptide functionalized curdlan nanoparticles | |
| RU2019106501A (ru) | Композиции и способы для лечения рака с истощающими аргинин и иммуноонкологическими агентами | |
| RU2010143715A (ru) | Терапевтическое применение новых фармацевтических препаратов, содержащих противоопухолевые лекарственные средства, связанные с гиалуроновой кислотой, в лечении неоплазий | |
| Ou et al. | RETRACTED ARTICLE: Efficient miRNA Inhibitor with GO-PEI Nanosheets for Osteosarcoma Suppression by Targeting PTEN | |
| Chen et al. | A codelivery system loaded with PDL1-siRNA and sorafenib enhances the therapeutic effect of sorafenib on hepatocellular carcinoma via TAT-poly-SS-lysine modified chitosan | |
| Assi et al. | Arginine deprivation as a treatment approach targeting cancer cell metabolism and survival: A review of the literature | |
| Li et al. | Transformable albumin-based nanocapsules selectively amplify tumor starvation and disulfidptosis through metabolic deception | |
| Zygmunt et al. | Metabolism and structure of PDA as the target for new therapies: possibilities and limitations for nanotechnology | |
| JP2015505557A5 (enExample) | ||
| JP7223502B6 (ja) | 医薬組成物 |